- Home
- PRT vs THTX Comparison
PRT vs THTX Comparison
Compare PRT & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- THTX
- Stock Information
- Founded
- PRT 2017
- THTX 1993
- Country
- PRT United States
- THTX Canada
- Employees
- PRT N/A
- THTX N/A
- Industry
- PRT Oil & Gas Production
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- THTX Health Care
- Exchange
- PRT Nasdaq
- THTX Nasdaq
- Market Cap
- PRT 45.4M
- THTX 54.3M
- IPO Year
- PRT N/A
- THTX N/A
- Fundamental
- Price
- PRT $3.37
- THTX $1.79
- Analyst Decision
- PRT
- THTX Hold
- Analyst Count
- PRT 0
- THTX 1
- Target Price
- PRT N/A
- THTX N/A
- AVG Volume (30 Days)
- PRT 51.1K
- THTX 85.1K
- Earning Date
- PRT 11-13-2024
- THTX 10-10-2024
- Dividend Yield
- PRT 11.61%
- THTX N/A
- EPS Growth
- PRT N/A
- THTX N/A
- EPS
- PRT 0.42
- THTX N/A
- Revenue
- PRT $6,059,380.00
- THTX $84,316,000.00
- Revenue This Year
- PRT N/A
- THTX $5.60
- Revenue Next Year
- PRT N/A
- THTX $4.62
- P/E Ratio
- PRT $8.58
- THTX N/A
- Revenue Growth
- PRT N/A
- THTX 5.75
- 52 Week Low
- PRT $3.41
- THTX $1.08
- 52 Week High
- PRT $5.03
- THTX $2.58
- Technical
- Relative Strength Index (RSI)
- PRT 36.42
- THTX 70.56
- Support Level
- PRT $3.41
- THTX $1.40
- Resistance Level
- PRT $4.05
- THTX $1.56
- Average True Range (ATR)
- PRT 0.14
- THTX 0.12
- MACD
- PRT -0.03
- THTX 0.03
- Stochastic Oscillator
- PRT 26.82
- THTX 96.65
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.